Rhythm Pharmaceuticals, Inc.
RYTM
Kedudukan dalam Saham
#3009
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial... Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Harga Saham
$88.46
Modal Pasaran
$6.09B
Perubahan (1 hari)
-1.93%
Perubahan (1 tahun)
-17.45%
Negara
US
Perdagangan Rhythm Pharmaceuticals, Inc. (RYTM)
Kategori
Healthcare
Sejarah harga saham bagi Rhythm Pharmaceuticals, Inc. (RYTM)
Harga penutupan tertinggi: $89.50 pada 2026-10-01
Harga penutupan terendah: $24.67 pada 2017-10-01
Harga penutupan terendah: $24.67 pada 2017-10-01
Sejarah harga saham Rhythm Pharmaceuticals, Inc. dari 2017 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2026 (TTM) | -8.85% |
| 2025 | 91.54% |
| 2024 | 34.76% |
| 2023 | 48.81% |
| 2022 | 174.77% |
| 2021 | -64.82% |
| 2020 | 24.27% |
| 2019 | -12.59% |
| 2018 | -6.07% |
| 2017 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
